Clinical Research
Value of subtypes of antimitochondrial antibodies in primary biliary cholangitis
Yang Hongyan, Zhao Liling, Zhang Shulan, Hu Zhaojun, Zeng Xiaofeng, Zhang Fengchun
Published 2021-08-15
Cite as Chin J Rheumatol, 2021, 25(8): 525-528. DOI: 10.3760/cma.j.cn141217-20210311-00096
Abstract
ObjectiveTo investigate the distribution and clinical significance of subtypes of antimitochondrial antibodies (AMA)-M2, M4, M9 in primary biliary cholangitis (PBC).
MethodsA total of 1 367 patients were detected with AMA-M2, M4, M9 in Peking Union Medical College Hospital (PUMCH) from Jan 2014 to Dec 2019 and the clinical parameters were collected. The distribution patterns of AMA subtypes in different groups were analyzed and the diagnostic sensitivity and specificity of AMA subtypes in PBC were calculated. Chi-square test was used for statistical analysis.
ResultsIn 1 367 patients, 236 of whom were positive for AMA subtypes. The positivity of AMA subtypes in female was significantly higher than in male (20.34% vs 9.41%, χ2=23.792, P<0.01). In addition, the positivity of AMA subtypes was significantly higher in 30-65 years old patients than in patients younger than 30 years old or older than 65 years old [(20.00%(193/965)vs 10.97%(17/155) vs 10.53%(26/247), χ2=17.209, P<0.01]. 110 patients with positive AMA subtypes were diagnosed with PBC. The diagnostic sensitivity and specificity of AMA-M2 were both desirable [94.64%(106/112) and 92.35%(1 159/1 255)]. Although the specificity of AMA-M4 was as high as 99.12%(1 244/1 255), its sensitivity was very low [15.18%(17/122)]. Combined detection of different AMA subtypes could not improve the diagnostic sensitivity and specificity significantly. Diseases other than PBC can be positive for AMA subtypes, predominantly for AMA-M2.
ConclusionFemale and 30-65 years old patients were more frequently positive for AMA subtypes. AMA-M2 was the most valuable AMA subtype for diagnosing PBC.
Key words:
Cholangitis; Antimitochondrial antibody; Protein Isoforms
Contributor Information
Yang Hongyan
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (the Ministy of Education Key Laborary, National Clinical Research Center for Dermatologic and Immunologic Diseases), Beijing 100730, China
Yang Hongyan Works in the Department of Heumatology and Rheumatology, Qinghai Provincial People's Hospital, Xining 810007, China
Zhao Liling
Department of Rheumatic Immunology, Tsinghua Changgung Hospital, Tsinghua University School of Medicine, Beijing 202218, China
Zhang Shulan
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (the Ministy of Education Key Laborary, National Clinical Research Center for Dermatologic and Immunologic Diseases), Beijing 100730, China
Hu Zhaojun
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (the Ministy of Education Key Laborary, National Clinical Research Center for Dermatologic and Immunologic Diseases), Beijing 100730, China
Zeng Xiaofeng
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (the Ministy of Education Key Laborary, National Clinical Research Center for Dermatologic and Immunologic Diseases), Beijing 100730, China
Zhang Fengchun
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (the Ministy of Education Key Laborary, National Clinical Research Center for Dermatologic and Immunologic Diseases), Beijing 100730, China
